Thomas Simmerer takes over sales at Carl Zeiss Meditec

Succeeds Ulrich Krauss as member of the management board with responsibility for sales

Thomas Simmerer has taken over as a member of the management board responsible for sales at Carl Zeiss Meditec in Germany. He succeeds Ulrich Krauss who has transferred to the management board of Carl Zeiss Vision International, a subsidiary of the Carl Zeiss Group.

‘I am looking forward to my new responsibilities and will maintain and expand the successful sales and service structure at Carl Zeiss Meditec in the respective markets,’ said Simmerer.

Simmerer has extensive experience in medical technology. He was in charge of the Microsurgery strategic business unit in Oberkochen from October 2008. Before joining the medical wing of Carl Zeiss, the mechanical engineer led the top-performing business unit, among others, of Dräger Medical in Lübeck from 1996 to 2008. Prior to this, he was responsible for different sales areas at Heraeus in Hanau.

You may also like

Pharma 5.0
ZEISS and Concept Life Sciences partner to advance automated workflows and AI-powered image analysis in spatial biology

ZEISS and Concept Life Sciences partner to advance automated workflows and AI-powered image analysis in spatial biology

The collaboration focusses on high-throughput imaging, AI-driven data analysis and streamlined integration into lab systems, aiming to improve efficiency and data quality for areas such as drug discovery and cancer research
Research & Development
ZEISS launches initiative to work closely with scientists during experiments

ZEISS launches initiative to work closely with scientists during experiments

The company is set to partner with leading research institutions such as Max Planck Florida Institute for Neuroscience, where they will be working closely with scientists
Research & Development
Medicines Discovery Catapult and ZEISS set sights on advancing microscopy in drug discovery

Medicines Discovery Catapult and ZEISS set sights on advancing microscopy in drug discovery

Medicines Discovery Catapult (MDC) and ZEISS have joined forces to improve drug discovery and early development of complex medicines by harnessing the power of advanced microscopy solutions
Manufacturing
Delivering cutting-edge technology

Delivering cutting-edge technology

WITec and ZEISS have collaborated to provide a fully integrated instrument, featuring a standard, unmodified vacuum chamber and scanning electron microscope (SEM) column along with a complete confocal Raman microscope and spectrometer
Research & Development
Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal

Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal

Cambridge-based biotech Mission Therapeutics has divested its Phase II-ready USP30 inhibitor MTX652 to renal specialist Dimerix in a deal worth up to $292m, allowing the company to accelerate its Parkinson’s disease pipeline
Pharma 5.0
FPT launches MediSight AI framework to accelerate pharma digital transformation and regulatory compliance

FPT launches MediSight AI framework to accelerate pharma digital transformation and regulatory compliance

The new AI-powered platform combines autonomous digital workers, interoperable healthcare data and compliance tools to help pharmaceutical manufacturers, medical device companies and healthcare providers scale AI adoption
Regulatory
Early phase analytical strategy for biosimilars in a shifting regulatory landscape

Early phase analytical strategy for biosimilars in a shifting regulatory landscape

As FDA and EMA guidance continues to reinforce analytical comparability as the foundation of biosimilar development, investing in comprehensive early-stage characterisation is becoming essential to reduce uncertainty and improve development outcomes, says Dr Andrew J. Reason, CEO at BioPharmaSpec
Subscribe now